Conclusion
In order to recover the symptoms and signs, new and easily accessible
drugs are required for use in the acute period of Peyronie’s disease. In
this context, treatment with intralesional low dose methylprednisolone
in acute phase Peyronie’s Disease is a promising and safe treatment
option.